Pancreas Neoplasm Clinical Trial
Official title:
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy: A Randomized Control Trial
The goal of this clinical trial is to analyze if intraperitoneal drainage is necessary following distal pancreatectomy. This study aims to determine whether the omission of routine intraperitoneal drainage in the setting of reinforced staple technology is non-inferior to routine intraperitoneal drainage with respect to a composite post-operative complications of Grade B or C Postoperative pancreatic fistula (POPF), readmission, or organ space surgical site infection following a distal pancreatectomy.
Status | Recruiting |
Enrollment | 234 |
Est. completion date | July 31, 2027 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects must be undergoing a scheduled distal pancreatectomy (with or without concurrent splenectomy) - Age =18 years - Subjects must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Patients < 18 years old - Patients who are pregnant - Patients with a history of previous pancreatic surgery - Patients with a history of prior gastric resection, gastric bypass or sleeve gastrectomy - Patients with prior cystogastrostomy procedure - Patients who have failed prior endoscopic intervention or ultrasound due to esophageal or other gastrointestinal stricture - Patients with Type 3 or Type 4 Paraesophageal Hernia noted either on pre-operative imaging or intra-operatively - Patients undergoing concurrent resection of organs other than the pancreas or spleen or gallbladder - Patients who undergo oversewing of the pancreatic transection margin - Patients with unexpected intraoperative bleeding or adhesive disease which deem it unsafe to proceed without an intraabdominal drain - Patients who are unable to provide informed consent |
Country | Name | City | State |
---|---|---|---|
United States | Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
Case Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composite endpoint comparison | Comparison between groups using a composite endpoint of complications that includes presence of Grade B POPF | Within 90 days of surgery | |
Primary | Composite endpoint comparison | Comparison between groups using a composite endpoint of complications that includes presence of Grade C POPF | Within 90 days of surgery | |
Primary | Composite endpoint comparison | Comparison between groups using a composite endpoint of complications that includes Readmission | Within 90 days of surgery | |
Primary | Composite endpoint comparison | Comparison between groups using a composite endpoint of complications that includes presence of Organ Space Surgical Site Infection | Within 90 days of surgery | |
Secondary | Rates of endoscopic drainage vs percutaneous drainage of Grade B POPF | Rates of drainage based off of the Grade B Postoperative pancreatic fistula | 90-day post operative time point | |
Secondary | Quality of Life Score | Post-operative Quality of Life score using the PROMIS-10 Global Health | At day 14 postoperative | |
Secondary | Quality of Life Score | Post-operative Quality of Life score using the PROMIS-10 Physical Function | At day 14 postoperative | |
Secondary | Quality of Life Score | Post-operative Quality of Life score using the original Drain Quality of Life scale | At day 14 postoperative | |
Secondary | Quality of Life Score | Post-operative Quality of Life score using the PROMIS-10 Global Health | At day 90 postoperative | |
Secondary | Quality of Life Score | Post-operative Quality of Life score using the PROMIS-10 Physical Function | At day 90 postoperative | |
Secondary | Quality of Life Score | Post-operative Quality of Life score using the original Drain Quality of Life scale | At day 90 postoperative | |
Secondary | Hospital Length of Stay | Measurement of the difference in Hospital Length-of-Stay based on intraperitoneal drainage after DP | 90-day post operative time point | |
Secondary | Cost analysis for overall healthcare costs | Cost analysis for overall healthcare costs associated with both methods of postoperative care | At day 90 postoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Recruiting |
NCT05155878 -
Prognostic Factors in Periampullary Tumors and Cysts
|
||
Completed |
NCT03834701 -
Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms
|
N/A | |
Recruiting |
NCT04164602 -
The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
|
||
Active, not recruiting |
NCT05095831 -
EUS Shear Wave for Solid Pancreatic Lesions.
|
||
Recruiting |
NCT04783844 -
Usefulness of 3D Digital Reconstruction in the Imaging Diagnosis of Pancreatic Tumors
|
||
Recruiting |
NCT03570502 -
Incidence of POPF in the Resection of the Left Pancreas With RFAT
|
||
Recruiting |
NCT04783831 -
Biodegradable Pancreatic Stents for the Prevention of Postoperative Pancreatic Fistula After Cephalic Pancreaticoduodenectomy
|
||
Not yet recruiting |
NCT06381882 -
The Role of the Human Microbiome in Patients After Pancreatic Resection.
|
||
Not yet recruiting |
NCT04336839 -
Portal Vein Resection in Pancreatic Neuroendocrine Tumours
|
||
Recruiting |
NCT05714111 -
Radiology Registry on Pancreatic Malignancies
|
||
Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06344507 -
Iconographic Registry of Pancreatobiliary Endoscopy Procedures
|
||
Recruiting |
NCT04104230 -
Quebec Pancreas Cancer Study
|
||
Recruiting |
NCT05371223 -
Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal Metastases
|
Phase 2 | |
Recruiting |
NCT04687410 -
Novel Crown-cut Biopsy Needle (FNB) vs Standard Aspiration Needle (FNA) for EUS-guided Diagnosis of SPLs
|
N/A | |
Completed |
NCT04724551 -
The Neutrophil-to-Lymphocyte Ratio to Exclude Pancreatic Fistula
|
||
Withdrawn |
NCT03649035 -
Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma
|
Phase 3 | |
Recruiting |
NCT04841616 -
Multicentered Prospective Randomized Controlled Trial For Solid Pancreatic Lesions
|
N/A | |
Completed |
NCT05711433 -
Risk Factors for Postoperative Pancreatic Fistula Following Non-traumatic Pancreatic Surgery. Retrospective Observational Study.
|